Cough Syrups & Mucolytics

Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).

Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).

Acetylcysteine Tablets / Effervescent Tablets (600mg) is an oral mucolytic and intracellular antioxidant precursor on the WHO Model List of Essential Medicines. Its free sulfhydryl (-SH) group chemically splits disulfide bonds in mucoprotein complexes, breaking cross-linked polymers and dramatically reducing the viscosity of purulent, thick bronchial mucus to facilitate expectoration. It also replenishes intracellular cysteine pools for glutathione synthesis, protecting lung tissues against oxidative stress. Indicated for acute and chronic bronchopulmonary disorders with excessive, viscous mucus (COPD, chronic bronchitis, bronchiectasis, cystic fibrosis) and contrast-induced nephropathy prevention.

Menthol (55 mg ± 5.) Cinnamon (12.5 mg ± 2) + Pine Oil (112.5 mg ± 1) Soft Capsules is an established pharmaceutical agent in the Respiratory & Allergy category on the PMBI National Formulary. Formulated to treat obstructive airway disease, cough, or allergic disorders according to verified pharmacopoeial standards.

Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).

Inhalant Softgel Capsules and Throat Sprays (Camphor, Menthol, Eucalyptol, Chlorothymol, Terpineol, Chamomile, Sage, Pine oil) is an aromatic essential oil steam inhalant and soothing throat formulation. When dissolved in hot water or sprayed, volatile vapors stimulate sensory trigeminal thermoreceptors (TRPM8), providing a subjective sensation of cool, unobstructed nasal breathing, while exerting mild antiseptic and secretomotor action on the respiratory tract. Indicated for symptomatic relief of nasal congestion, cold symptoms, catarrh, and sore throat.

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Dextromethorphan Hydrobromide Syrup (13.5mg/5ml), Lozenges (5mg; alone or with Phenylephrine and Chlorpheniramine) is an oral centrally acting non-opioid antitussive on the WHO Model List of Essential Medicines. It acts as an agonist at sigma-1 receptors and a non-competitive antagonist at NMDA glutamate receptors in the medullary cough center of the brainstem, raising the threshold for coughing without suppressing respiratory drive, inhibiting mucociliary clearance, or causing opioid dependence. Indicated for temporary relief of dry, hacking, non-productive cough caused by minor throat and bronchial irritation from the common cold or inhaled irritants.

Acetylcysteine Injection (200mg/ml) is a sterile parenteral mucolytic and life-saving antidote on the WHO Model List of Essential Medicines. In paracetamol (acetaminophen) overdose, it replenishes depleted intracellular hepatic glutathione stores and conjugates directly with toxic NAPQI (N-acetyl-p-benzoquinone imine), preventing fatal hepatic centrilobular necrosis. Indicated as the specific antidote for acute paracetamol overdose and as an intravenous mucolytic in atelectasis / thick mucous plugging.

Noscapine Syrup (1.83mg per 5ml) is a natural benzylisoquinoline alkaloid antitussive derived from the opium poppy (Papaver somniferum) on the WHO Model List framework. It acts centrally as a potent sigma receptor agonist to suppress the medullary cough reflex, while completely lacking opioid analgesia, respiratory depression, constipation, or addiction liability. Indicated for relief of dry, irritating, non-productive cough.

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Acebrophylline Capsules / Tablets (100mg, 200mg Sustained Release; alone or with Montelukast 10mg or Acetylcysteine 600mg) is a fixed salt of ambroxol and theophylline-7-acetic acid on the PMBI formulary. It exerts a triple therapeutic action: potent bronchodilation via phosphodiesterase inhibition; mucoregulatory and surfactant-stimulating action via ambroxol (stimulating alveolar type II pneumocytes to produce pulmonary surfactant, reducing mucus viscosity and improving mucociliary clearance); and anti-inflammatory inhibition of phospholipase A2 and leukotriene C4. Indicated for bronchial asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic spastic bronchitis with thick viscid sputum.

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Acetylcysteine Tablets / Effervescent Tablets (600mg) is an oral mucolytic and intracellular antioxidant precursor on the WHO Model List of Essential Medicines. Its free sulfhydryl (-SH) group chemically splits disulfide bonds in mucoprotein complexes, breaking cross-linked polymers and dramatically reducing the viscosity of purulent, thick bronchial mucus to facilitate expectoration. It also replenishes intracellular cysteine pools for glutathione synthesis, protecting lung tissues against oxidative stress. Indicated for acute and chronic bronchopulmonary disorders with excessive, viscous mucus (COPD, chronic bronchitis, bronchiectasis, cystic fibrosis) and contrast-induced nephropathy prevention.

Dextromethorphan Hydrobromide Syrup (13.5mg/5ml), Lozenges (5mg; alone or with Phenylephrine and Chlorpheniramine) is an oral centrally acting non-opioid antitussive on the WHO Model List of Essential Medicines. It acts as an agonist at sigma-1 receptors and a non-competitive antagonist at NMDA glutamate receptors in the medullary cough center of the brainstem, raising the threshold for coughing without suppressing respiratory drive, inhibiting mucociliary clearance, or causing opioid dependence. Indicated for temporary relief of dry, hacking, non-productive cough caused by minor throat and bronchial irritation from the common cold or inhaled irritants.

Levocloperastine (20mg/5ml) and Levodropropizine (30mg/5ml) Syrup is a non-opioid peripheral and central antitussive on the PMBI formulary. Acts primarily on peripheral sensory receptors in the tracheobronchial tree (inhibiting C-fiber sensory neuropeptide release) and selectively suppresses the central cough center without causing sedation, somnolence, respiratory depression, or constipation. Indicated for symptomatic treatment of irritating dry non-productive cough of various etiologies.